Experimental immune therapy takes on tough pancreatic cancer

NCT ID NCT06479239

Recruiting now Disease control Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment called EGFR FPBMC for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The treatment uses a patient's own immune cells, which are modified in the lab to better attack cancer cells, then given back through an IV. The goal is to see if it is safe and if it can shrink tumors or slow the disease. The trial is recruiting 23 participants at the University of Virginia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EGFR FPBMC (a type of immune cell therapy that targets cancer cells)
What this could lead to: If it works, this could offer a new treatment option for people with advanced pancreatic cancer that has not responded to standard chemotherapy.
What could go wrong: This is an early-phase trial with only 23 participants, so the results may not apply to everyone. The treatment may cause side effects or not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREAS CANCER PANCREATIC CANCER

Contacts and locations

Locations

University of Virginia
RECRUITING

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.